Eribulin mesylate
نویسندگان
چکیده
منابع مشابه
Eribulin mesylate in the treatment of metastatic breast cancer
The treatment of metastatic breast cancer (MBC) has become increasingly challenging as the primary goals of therapy include prolonging life without added toxicity. While multiple agents are approved for the therapy of MBC, there is no standard approach for therapy beyond the second-line. Eribulin mesylate, an analog of the marine sponge halichondrin B, is a non-taxane microtubule dynamics inhib...
متن کاملEribulin Mesylate Combined with Local Treatment for Brain Metastasis from Breast Cancer: Two Case Reports
The prognosis associated with brain metastasis arising from breast cancer is very poor. Eribulin is a microtubule dynamic inhibitor synthesized from halichondrin B, a natural marine product. In a phase III study (EMBRACE), eribulin improved overall survival in patients with heavily pretreated metastatic breast cancers. However, these studies included few patients with brain metastases. Metastat...
متن کاملAntitumor Effects of Eribulin Mesylate in Gemcitabine-resistant Pancreatic Cancer Cell Lines.
BACKGROUND/AIM One reason of poor survival rate of patients with pancreatic cancer is the development of chemoresistance. The aim of the present study was to investigate the effects of eribulin mesylate in gemcitabine-refractory advanced pancreatic cancer cell lines. MATERIALS AND METHODS Three human pancreatic cancer cell lines (AsPC-1, Panc-1, and SUIT-2) and human pancreatic endoderm (hPE)...
متن کاملEribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models
Eribulin mesylate is a synthetic macrocyclic ketone analog of the marine sponge natural product halichondrin B and an inhibitor of microtubule dynamics. Some tubulin-binding drugs are known to have antivascular (antiangiogenesis or vascular-disrupting) activities that can target abnormal tumor vessels. Using dynamic contrast-enhanced MRI analyses, here we show that eribulin induces remodeling o...
متن کاملClinical evidence for the role of eribulin mesylate in the treatment of breast cancer
The development of drugs improving overall survival (OS) in late-stage metastatic breast cancer (MBC) remains a challenge. Eribulin mesylate, a new chemotherapy agent, has shown significant results in this setting. This agent is a synthetic analog of a macrolide isolated from a marine sponge. It inhibits microtubule polymerization, inducing mitotic arrest and apoptosis, and aggregates soluble t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Reviews Drug Discovery
سال: 2011
ISSN: 1474-1776,1474-1784
DOI: 10.1038/nrd3389